Serum-Associated Antibiotic Tolerance in Pediatric Clinical Isolates of Pseudomonas aeruginosa.
antibiotic resistance
antibiotic tolerance
cystic fibrosis
drug efflux
tracheitis
Journal
Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049
Informations de publication
Date de publication:
31 Dec 2020
31 Dec 2020
Historique:
received:
25
06
2019
accepted:
05
12
2019
pubmed:
31
12
2019
medline:
19
8
2021
entrez:
31
12
2019
Statut:
ppublish
Résumé
When grown in human serum, laboratory isolates of Pseudomonas aeruginosa exhibit tolerance to antibiotics at inhibitory concentrations. This phenomenon, known as serum-associated antibiotic tolerance (SAT), could lead to clinical treatment failure of pseudomonal infections. Our purpose in this study was to determine the prevalence and clinical impact of SAT in Pseudomonas isolates in hospitalized children. The SAT phenotype was assessed in patients aged <18 years admitted with respiratory or blood cultures positive for P. aeruginosa. The SAT phenotype was a priori defined as a ≥2-log increase in colony-forming units when grown in human serum compared with Luria-Bertani medium in the presence of minocycline or tobramycin. SAT was detected in 29 (64%) patients. Fourteen patients each (34%) had cystic fibrosis (CF) and tracheostomies. Patient demographics and comorbidities did not differ by SAT status. Among CF patients, SAT was associated with longer duration of intravenous antibiotics (10 days vs 5 days; P < .01). This study establishes that SAT exists in P. aeruginosa from human serum and may be a novel factor that contributes to differences in clinical outcomes. Future research should investigate the mechanisms that contribute to SAT in order to identify novel targets for adjunctive antimicrobial therapies.
Sections du résumé
BACKGROUND
BACKGROUND
When grown in human serum, laboratory isolates of Pseudomonas aeruginosa exhibit tolerance to antibiotics at inhibitory concentrations. This phenomenon, known as serum-associated antibiotic tolerance (SAT), could lead to clinical treatment failure of pseudomonal infections. Our purpose in this study was to determine the prevalence and clinical impact of SAT in Pseudomonas isolates in hospitalized children.
METHODS
METHODS
The SAT phenotype was assessed in patients aged <18 years admitted with respiratory or blood cultures positive for P. aeruginosa. The SAT phenotype was a priori defined as a ≥2-log increase in colony-forming units when grown in human serum compared with Luria-Bertani medium in the presence of minocycline or tobramycin.
RESULTS
RESULTS
SAT was detected in 29 (64%) patients. Fourteen patients each (34%) had cystic fibrosis (CF) and tracheostomies. Patient demographics and comorbidities did not differ by SAT status. Among CF patients, SAT was associated with longer duration of intravenous antibiotics (10 days vs 5 days; P < .01).
CONCLUSIONS
CONCLUSIONS
This study establishes that SAT exists in P. aeruginosa from human serum and may be a novel factor that contributes to differences in clinical outcomes. Future research should investigate the mechanisms that contribute to SAT in order to identify novel targets for adjunctive antimicrobial therapies.
Identifiants
pubmed: 31886511
pii: 5690156
doi: 10.1093/jpids/piz094
pmc: PMC7974018
doi:
Substances chimiques
Anti-Bacterial Agents
0
Tobramycin
VZ8RRZ51VK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
671-679Subventions
Organisme : NIDCR NIH HHS
ID : T90 DE021985
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1633-7
pubmed: 8256912
Am J Respir Crit Care Med. 1998 Jan;157(1):10-4
pubmed: 9445271
J Cyst Fibros. 2018 May;17(3):341-347
pubmed: 29110966
J Pediatr. 2007 Aug;151(2):134-9, 139.e1
pubmed: 17643762
J Infect Dis. 1974 Nov;130(5):454-63
pubmed: 4370727
Antimicrob Agents Chemother. 2011 Feb;55(2):508-14
pubmed: 21078928
Antimicrob Agents Chemother. 2014 Nov;58(11):6360-70
pubmed: 25114126
Int J Antimicrob Agents. 2011 Mar;37(3):187-93
pubmed: 21295448
Curr Drug Targets. 2016;17(6):702-19
pubmed: 26424403
Int J Antimicrob Agents. 2009 Aug;34 Suppl 3:S14-9
pubmed: 19596109
Respir Care. 2016 Apr;61(4):447-52
pubmed: 26670471
Am J Physiol Lung Cell Mol Physiol. 2004 Jun;286(6):L1095-104
pubmed: 14742308
J Antimicrob Chemother. 2002 Nov;50(5):657-64
pubmed: 12407121
Antimicrob Agents Chemother. 2001 Jul;45(7):1964-71
pubmed: 11408209
Antimicrob Agents Chemother. 1999 Dec;43(12):2975-83
pubmed: 10582892
Antimicrob Agents Chemother. 1999 Nov;43(11):2624-8
pubmed: 10543738
Antimicrob Agents Chemother. 2004 May;48(5):1676-80
pubmed: 15105120
Hosp Pediatr. 2018 Jan 16;:
pubmed: 29339536
Science. 2011 Nov 18;334(6058):982-6
pubmed: 22096200
Respiration. 2006;73(1):27-33
pubmed: 16113513
Am Rev Respir Dis. 1981 Jul;124(1):72-9
pubmed: 6789730
J Cyst Fibros. 2016 Nov;15(6):776-782
pubmed: 27143583
Semin Cell Dev Biol. 2001 Jun;12(3):225-37
pubmed: 11428915
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28507116
Antimicrob Agents Chemother. 2004 May;48(5):1797-802
pubmed: 15105137
Antibiotics (Basel). 2013 Mar 18;2(1):163-81
pubmed: 27029297
Am J Respir Crit Care Med. 2013 Jul 1;188(1):69-76
pubmed: 23641973
Biotechnol Adv. 2019 Jan - Feb;37(1):177-192
pubmed: 30500353
Trends Microbiol. 2016 May;24(5):327-337
pubmed: 26946977
Antimicrob Agents Chemother. 1995 Sep;39(9):1948-53
pubmed: 8540696
Antimicrob Agents Chemother. 1998 Sep;42(9):2225-31
pubmed: 9736539
Mol Cell Proteomics. 2005 Sep;4(9):1251-64
pubmed: 15951573
Clin Infect Dis. 2013 Apr;56(7):978-87
pubmed: 23264361
Int J Med Microbiol. 2017 Sep;307(6):353-362
pubmed: 28754426
Pediatrics. 2017 Feb;139(2):
pubmed: 28126911
J Antimicrob Chemother. 2017 Jun 1;72(6):1632-1634
pubmed: 28333250
Cell Calcium. 2017 Jan;61:32-43
pubmed: 28034459
Microorganisms. 2016 Feb 16;4(1):
pubmed: 27681908
Clin Infect Dis. 2009 Jan 1;48(1):1-12
pubmed: 19035777
Pediatr Pulmonol. 1992 Mar;12(3):158-61
pubmed: 1641272
BMJ. 2014 Sep 23;349:g5493
pubmed: 25249162
Pediatr Pulmonol. 2001 Oct;32(4):277-87
pubmed: 11568988
Klin Wochenschr. 1985 Sep 2;63(17):781-7
pubmed: 4057910
Front Microbiol. 2018 Nov 23;9:2752
pubmed: 30532741
FEMS Immunol Med Microbiol. 2012 Apr;64(3):403-12
pubmed: 22211672
Antimicrob Agents Chemother. 2014 Jul;58(7):3904-13
pubmed: 24777101
Hosp Pediatr. 2017 Jan;7(1):16-23
pubmed: 27998905
Clin Pharmacol Ther. 1978 Mar;23(3):356-60
pubmed: 627143
Pediatr Pulmonol. 2015 Jan;50(1):42-8
pubmed: 24644274
Front Microbiol. 2012 Nov 28;3:408
pubmed: 23233851
Antimicrob Agents Chemother. 2010 Mar;54(3):1029-41
pubmed: 20028819
Antimicrob Agents Chemother. 1996 Oct;40(10):2288-90
pubmed: 9036831
PLoS Genet. 2006 Jan;2(1):e7
pubmed: 16415984
Infect Immun. 2017 Aug 18;85(9):
pubmed: 28630071
Antimicrob Agents Chemother. 2010 Mar;54(3):1160-4
pubmed: 20086165
J Bacteriol. 1998 Oct;180(20):5443-7
pubmed: 9765578
Sci Rep. 2017 Sep 12;7(1):11392
pubmed: 28900249